Enclomiphene Citrate Geriatric (65+) Monitoring: Lab Schedule, Safety Checks, and Dose Adjustments

Is there a monitoring protocol for men over 65?

No. No FDA-approved drug contains enclomiphene as an active ingredient, so there is no label that sets a monitoring schedule, and EMA refused marketing authorisation for EnCyzix (enclomifene) in January 2018 [2][3].

Who was actually studied

The 12-week phase 3 efficacy trials enrolled overweight men aged 18 to 60 with secondary hypogonadism and morning testosterone at or under 300 ng/dL [5][7][1]. In ZA-302, 81.3% of enclomiphene-treated men reached an average 24-hour testosterone of 300 to 1040 ng/dL (95% CI 73.9 to 87.0, n=134); the trial enrolled 181 men overall [7]. The two 16-week comparisons against AndroGel 1.62% also used men aged 18 to 60 [1]. A separate 6-month open-label safety study enrolled 499 men aged 18 to 65 with secondary hypogonadism, taking 12.5 or 25 mg daily [9].

What regulators flagged

FDA's 2022 review listed cardiac and thromboembolic events — including pulmonary embolism and deep vein thrombosis in a safety study — plus raised estradiol, raised PSA and raised hematocrit, and noted there are no long-term safety data [2]. EMA saw a slightly higher rate of cardiac and thromboembolic events than with testosterone, found cataracts in nonclinical studies and wanted ocular monitoring; its refusal rested on four main studies in 588 patients and cited venous thromboembolism risk [2][3]. A 2026 British Society of Sexual Medicine position statement advises use only in specialist or research settings because long-term efficacy and safety data are lacking [8].

What the clomiphene label says, and does not

The available FDA label is for clomiphene citrate (Clomid), the mixture of enclomiphene and zuclomiphene, approved only for ovulatory dysfunction in women who want to conceive [6]. It has no male indication and states that there are no adequate or well-controlled studies demonstrating effectiveness in male infertility; testicular tumors and gynecomastia have been reported in men using clomiphene, with cause and effect not known [6]. It warns of blurring, spots or flashes that increase with dose and duration and may be prolonged or irreversible, and the label says patients with any visual symptoms should discontinue treatment and have a complete ophthalmological evaluation carried out promptly [6]. It contraindicates use in liver disease, uncontrolled thyroid or adrenal dysfunction, pituitary tumor and pregnancy [6]. All of this describes the mixture, not enclomiphene alone.

Doses studied

No approved dose exists [2]. Phase 3 protocols used 12.5 mg once daily, up-titrated to 25 mg at week 6 if morning testosterone stayed below 300 ng/dL [5], and an earlier dose-finding study also tested 6.25 mg [4]. Because there is no approved dose, there is also no approved adjustment for age, kidney function or liver function. The liver-disease contraindication in the Clomid label applies to clomiphene, not enclomiphene alone [6].

Side effects recorded in the trials

The most frequent were headache, hot flushes, nausea and muscle spasm, and reasons for stopping included blurred vision, muscle spasm, headache and aggression [7]. In ZA-302, headache was reported by 7 of 112 men on 12.5 mg versus 1 of 47 on placebo, and nausea by 4 of 112 versus 3 of 47 [7].